Lipoxal

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Convection-enhancement delivery of liposomal formulation of oxaliplatin shows less toxicity than oxaliplatin yet maintains a similar median survival time in F98 glioma-bearing rat model
Results of clinical trials with oxaliplatin in treating glioblastoma are dismal. Previous works showed that intravenous (i.v… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
2014
2014
New therapeutic possibilities of combined treatment of radiotherapy with oxaliplatin and its liposomal formulation, Lipoxalâ„¢, in rectal cancer using xenograft in nude mice.
AIM To determine the benefits of irradiation at the time of maximum linking of oxaliplatin to the DNA of tumor cells, and… (More)
Is this relevant?
Review
2014
Review
2014
Surface modified multifunctional nanomedicines for simultaneous imaging and therapy of cancer
INTRODUCTION To date, a growing number of advanced anticancer nanomedicines (e.g., Doxil(®), Lipoxal(®), DepoCyte(®)) have… (More)
  • figure 1
  • table 1
  • figure 3
  • figure 2
  • figure 4
Is this relevant?
2013
2013
Optimization of the route of platinum drugs administration to optimize the concomitant treatment with radiotherapy for glioblastoma implanted in the Fischer rat brain
Treatment of glioblastoma with platinum compounds modestly improves progression-free survival and may cause toxic effects which… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
Is this relevant?
2012
2012
Glioblastoma treatment: bypassing the toxicity of platinum compounds by using liposomal formulation and increasing treatment efficiency with concomitant radiotherapy.
PURPOSE Treatments of glioblastoma with cisplatin or oxaliplatin only marginally improve the overall survival of patients and… (More)
Is this relevant?
2012
2012
Synergism in concomitant chemoradiotherapy of cisplatin and oxaliplatin and their liposomal formulation in the human colorectal cancer HCT116 model.
BACKGROUND We choose to test the effect of associating chemo-radiotherapy at 8 h (the highest level of DNA-platinum) and 48 h… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2010
2010
Cellular uptake and cytoplasm / DNA distribution of cisplatin and oxaliplatin and their liposomal formulation in human colorectal cancer cell HCT116
Liposomal formulations of cisplatin and oxaliplatin (Lipoplatin™ and Lipoxal™, respectively) were recently proposed to reduce… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 4
  • figure 3
Is this relevant?
2006
2006
MLH1-deficient tumor cells are resistant to lipoplatin, but retain sensitivity to lipoxal.
Lipoplatin, currently under phase III evaluation, is a novel liposomal cisplatin formulation highly effective against cancers… (More)
Is this relevant?
2006
2006
Liposomal oxaliplatin in the treatment of advanced cancer: a phase I study.
BACKGROUND Lipoxal is a liposomal oxaliplatin, which reduces the cytotoxic agent's adverse reactions without reducing… (More)
  • table I
  • table II
  • table III
  • figure 1
  • figure 2
Is this relevant?
2006
2006
Potential of the Akt inhibitor LY294005 to antagonize the efficacy of Cisplatin against HCT116 tumor cells in a DNA mismatch repair-dependent manner.
Human colorectal adenocarcinoma sublines either deficient (HCT116+ch2) or proficient (HCT116+ch3) in the function of MLH1, one of… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?